Whole-Blood Boundary Analysis of BioFET-Based ctDNA Detection for Intravascular Sensing in Intrabody Nanonetworks CCS: Computing methodologies Model development and analysis CCS: Computing methodologies Simulation types and techniques CCS: Computer systems organization Sensors and actuators CCS: Applied computing Life and medical sciences CCS: Networks Cyber-physical networks Conference: International Conference on Nanoscale Computing and Communication; September 21–23, 2026; St. John’s, Canada International Conference on Nanoscale Computing and Communication (NanoCom ’26), September 21–23, 2026, St. John’s, Canada ISBN: 979-8-4007-1171-8/24/10

Ida Kleger-Rudomin, Filip Lemic, Sergi Abadal, Eduard Alarcón, Ethungshan Shitiri · 2026

Read Whole-Blood Boundary Analysis of BioFET-Based ctDNA Detection for Intravascular Sensing in Intrabody Nanonetworks CCS: Computing methodologies Model development and analysis CCS: Computing methodologies Simulation types and techniques CCS: Computer systems organization Sensors and actuators CCS: Applied computing Life and medical sciences CCS: Networks Cyber-physical networks Conference: International Conference on Nanoscale Computing and Communication; September 21–23, 2026; St. John’s, Canada International Conference on Nanoscale Computing and Communication (NanoCom ’26), September 21–23, 2026, St. John’s, Canada ISBN: 979-8-4007-1171-8/24/10 by Ida Kleger-Rudomin, Filip Lemic, Sergi Abadal, Eduard Alarcón, Ethungshan Shitiri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2605-22637.txt.

Introduction

Kleger-Rudomin and others ask whether BioFET nanosensors, sensitive to tumour DNA in clean lab media, still detect it reliably in whole blood. Their simulation links operating point, screened charge transfer, finite binding, stray adsorption, background swings and electronic noise to a blank based threshold. Monte Carlo runs show short screening length and nanometre charge gaps weaken the current shift, while low frequency noise shrinks the gap to blank responses. Under the tested charge gating regime, simulated shifts fail to clear the threshold reliably at low tumour DNA levels.

Catalog record

CREATORIda Kleger-Rudomin, Filip Lemic, Sergi Abadal, Eduard Alarcón, Ethungshan Shitiri
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29505
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2605.22637

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Whole-Blood Boundary Analysis of BioFET-Based ctDNA Detection for Intravascular Sensing in Intrabody Nanonetworks CCS: Computing methodologies Model development and analysis CCS: Computing methodologies Simulation types and techniques CCS: Computer systems organization Sensors and actuators CCS: Applied computing Life and medical sciences CCS: Networks Cyber-physical networks Conference: International Conference on Nanoscale Computing and Communication; September 21–23, 2026; St. John’s, Canada International Conference on Nanoscale Computing and Communication (NanoCom ’26), September 21–23, 2026, St. John’s, Canada ISBN: 979-8-4007-1171-8/24/10 Ida Kleger-Rudomin, Filip Lemic, Sergi Abadal, Eduard Alarcón, Ethungshan Shitiri Abstract . Liquid biopsy can detect tumor-derived biomarkers such as circulating tumor DNA (ctDNA), but ultra-low-fraction assays remain costly, slow, and difficult to scale. This motivates interest in intravascular in vivo sensing in the context of intrabody nanonetworks, where nanosensors could support local biomarker monitoring. BioFET-based nanosensors are relevant here because they are label-free, highly miniaturizable, and have shown strong ctDNA sensitivity in controlled media. We examine whether this sensitivity still yields reliable ctDNA detection in whole blood using a reduced-order stochastic simulation model that links operating-point selection, Debye-screened charge transduction, stochastic finite-capacity binding, nonspecific adsorption, background fluctuations, and intrinsic electronic noise to blank-threshold detection. Monte Carlo evaluation with physiologically grounded parameters shows that short Debye length and several-nanometer charge-to-channel separation attenuate the current shift, while low-frequency noise and background fluctuations reduce the margin between target-present and blank responses. Under the tested quasi-static charge-gating regime, the simulated current shifts do not reliably exceed the blank-derived threshold at low ctDNA concentrations. The model therefore provides a whole-blood boundary analysis that identifies which interface configurations and operating conditions most strongly limit reliable BioFET-based intravascular ctDNA detection. 1. Introduction Early-stage cancer detection is important in oncology because outcomes improve when cancers are identified earlier, yet many are still diagnosed at advanced stages 34 ; 10 ; 20 . This need has increased interest in blood-based molecular diagnostics that aim to detect rare tumor-derived alterations in noisy clinical backgrounds. Liquid biopsy has therefore emerged as an important route to diagnosis and monitoring by enabling access to tumor-derived material from blood without invasive tissue procedures 20 ; 22 ; 30 ; 4 . Among liquid-biopsy analytes, circulating tumor DNA (ctDNA) is especially informative because it carries cancer-specific genetic alterations and supports quantitative tracking of disease dynamics 38 . The most demanding applications require detecting ctDNA at very low fractions amid a large background of non-tumor cell-free DNA (cfDNA), especially in early-stage disease and after treatment 22 ; 30 . In this regime, performance depends on mean signal level, counting uncertainty, and background interference. These factors increase assay burden and motivate sensing strategies that can reduce reliance on intermittent laboratory measurements 5 . Figure 1 . Whole-blood ctDNA sensing in an intrabody nanonetwork compared with conventional liquid biopsy. One response to this burden is to move sensing closer to the physiological site of interest so that molecular events can be detected in situ rather than inferred only from intermittent laboratory assays. Intrabody nanonetworks provide the broader systems context for this direction. In that framework, nanosensors detect local biochemical events and produce signals that can, in principle, be digitized and reported under tight size, power, and duty-cycling constraints 2 . Within that framework, intravascular sensing is especially relevant for ctDNA because blood carries the target and offers direct physiological access 29 . This study evaluates the separation between nanosensor responses with ctDNA present and target-absent whole-blood responses under physiological screening, background interference, and device noise. Fig. 1 summarizes this intrabody setting and the bottlenecks that motivate the exploration undertaken here. Biological field-effect transistors (BioFETs) are transistor-based nanosensors in which biomolecular binding at a functionalized surface changes the local electrostatic potential and shifts the channel current 21 . In the intravascular sensing setting, BioFETs are relevant because they are label-free, electrically integrated, and have already shown strong ctDNA sensitivity in buffer and serum 19 ; 25 . Their direct operation in whole blood remains strongly constrained because short Debye length, charge-to-channel separation caused by the interface stack, nonspecific adsorption, and intrinsic low-frequency noise can interfere with the signal 31 ; 18 ; 14 ; 16 . Work on high-ionic-strength and complex media has used local screening control, alternative measurement schemes, and interface engineering to recover charge coupling or measurement stability 15 ; 9 ; 6 . Recent studies have moved toward whole-blood BioFET operation through upstream matrix handling or analyte-specific architectures 31 ; 3 ; 27 . The broader whole-blood sensing literature also shows that intravascular operation is possible for selected analytes and mechanisms. Electrochemical aptamer-based sensors avoid Debye screening and have enabled seconds-resolved in vivo molecular measurements in circulating blood 13 . Enzyme amperometric sensors support long-duration metabolic monitoring in vivo 35 . Fiber-optic photoacoustic sensors have demonstrated intravascular whole-blood sensing for analytes such as dissolved gases and heparin 39 . We therefore use BioFET as a charge-based reference platform whose controlled-media ctDNA sensitivity and electrical compatibility make it informative for a whole-blood boundary analysis, while recognizing that direct whole-blood ctDNA sensing remains unestablished across platforms. We address this transfer question with a reduced-order stochastic simulation model for BioFET-based ctDNA sensing under practical whole-blood conditions. The model links operating-point selection, interface geometry, finite-capacity binding, screened transduction, background response, noise, and threshold-based detection in a single local-sensing pipeline. The main contributions are as follows. • We define intravascular ctDNA sensing as a blank-threshold detection problem under intrabody-compatible local sensing constraints, where detection depends on separation between target-present responses and target-absent whole-blood blank responses. • We develop a reduced-order stochastic simulation model that combines analytical BioFET charge coupling and blank-threshold detection with Monte Carlo sampling of target binding, cfDNA-like background fragments, and intrinsic current noise. • We quantify how oxide thickness, effective binding distance, ionic screening, and target concentration shape the transfer from controlled-media BioFET sensitivity to whole-blood detection performance, including regimes where high specificity coexists with weak sensitivity. The remainder of the paper is organized as follows. Section 2 presents the stochastic end-to-end system model linking ctDNA concentration to drain-current shifts and binary detection outcomes. Section 3 reports simulation results on screening-limited signal formation, sensitivity and specificity across interface and screening regimes, and the low-frequency noise floor that compresses the margin between target-present and blank responses. Section 4 then discusses the implications of these results, the model limitations, and design directions for future work. 2. ctDNA Sensing Model We define a reduced-order, quasi-static stochastic simulation model that maps ctDNA concentration in whole blood to a drain-current shift and a binary detection outcome. The model focuses on the local sensing stage. Device-specific implementation details and the intrabody reporting chain are outside the present scope. Fig. 2 highlights the modeled sensing stack and the whole-blood environment considered here. The model has four stages. First, it sets the operating point and baseline current. Second, it models surface occupancy by target and background fragments. Third, it converts bound charge into a Debye-screened current shift. Fourth, it estimates a blank-derived threshold and computes sensitivity and specificity. The term blank refers to measurements performed in the absence of target molecules, so the response reflects only background and noise contributions. 2.1. Operating Point and Baseline Current We first determine the electrical operating point because the sensing model measures current

Read the complete text